

INFORMAZIONI PERSONALI

Flavia Agata Cimini

ESPERIENZA
PROFESSIONALE

2025 – 2026

Post-doc Fellow

Hospital del Mar Medical Research Institute (IMIM) – Barcellona, Spagna

- Progetto: "Cognitive performance assessment in individuals with type 2 diabetes and MASLD and identification of clinical predictors and emerging biomarkers of cognitive decline". Responsabile: Prof. Rafael De La Torre.

2019 – 2021

Assegnista di Ricerca (Post-doc Fellow)

Dipartimento di Medicina Sperimentale, Sapienza Università di Roma – Roma, Italia

- Progetto: "From chronic inflammation to metabolic disorders: study of the gut-liver axis in the pathophysiology of adipose tissue dysfunction". Attività clinica autorizzata in reparto, Day-Hospital e ambulatori. Responsabile: Prof.ssa Maria Gisella Cavallo

ISTRUZIONE E FORMAZIONE

2021-2026

Specializzazione in Scienza dell'Alimentazione

Sapienza Università di Roma

2015-2019

Dottorato di Ricerca in Epatologia Sperimentale e Clinica

Sapienza Università di Roma

2008-2015

Laurea Magistrale in Medicina e Chirurgia

Sapienza Università di Roma

COMPETENZE PERSONALI

Lingua madre

Italiana

Altre lingue

Inglese

COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
Ascolto	Lettura	Interazione	Produzione orale	
C1	C1	C1	C1	C1

Livelli: A1/A2: Utente base - B1/B2: Utente intermedio - C1/C2: Utente avanzato

[Quadro Comune Europeo di Riferimento delle Lingue](#)

Competenze comunicative

- Ottime competenze comunicative acquisite nell'attività clinica con i pazienti, nella docenza universitaria, nella presentazione di ricerche scientifiche a congressi nazionali e internazionali.

Competenze organizzative e gestionali

- Coordinamento di attività di ricerca clinica e sperimentale. Co-investigatrice in trial clinici internazionali multicentrici. Supervisione di studenti di dottorato e co-supervisione di tesi magistrali. Gestione di collaborazioni scientifiche nazionali e internazionali.

Competenze professionali

- Esperienza clinica in Endocrinologia e Diabetologia (ambulatorio e Day-Hospital). Ricerca traslazionale su diabete mellito tipo 1 e tipo 2, MASLD/NAFLD, tessuto adiposo, vitamina D, metabolismo osseo, infiammazione sistemica. H-index 21 (Scopus e Web of Science); 62 pubblicazioni su riviste internazionali peer-reviewed; 1.520 citazioni (Scopus). ORCID: 0000-0001-

7630-7349.

Competenze digitali

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Livello avanzato	Livello avanzato	Livello avanzato	Livello avanzato	Livello avanzato

Livelli: Utente base - Utente intermedio - Utente avanzato

[Competenze digitali - Scheda per l'autovalutazione](#)

Patente di guida

Categoria B

ULTERIORI INFORMAZIONI

Pubblicazioni

1. Barchetta I, Cimini FA, Dule S, Passarella G, Oldani A, Hirsch MN, Cirelli M, Alfano M, Cavallo MG. Fibrotic NASH Index (FNI) Is Associated with Long-Term Mortality in Individuals with Type 2 Diabetes and MASLD. *Liver Int.* 2026 Jun;46(6):e70676. doi: 10.1111/liv.70676. PMID: 42130161; PMCID: PMC13172655.
2. Cimini FA, Cuenca-Royo A, Gomis-Gonzalez M, Forcano L, Barchetta I, Barone E, Cavallo MG, De La Torre R. Neuroprotective strategies for cognitive decline in type 2 diabetes. *Trends Endocrinol Metab.* 2026 Apr 28:S1043-2760(26)00095-0. doi: 10.1016/j.tem.2026.04.003. Epub ahead of print. PMID: 42055924.
3. Barchetta I, Cimini FA, Sentinelli F, Dule S, Frattina V, Passarella G, Hirsch MN, Oldani A, Baroni MG, Cavallo MG. Soluble CD14 Levels Predict Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Independently of Obesity and Type 2 Diabetes. *Int J Mol Sci.* 2026 Mar 27;27(7):3050. doi: 10.3390/ijms27073050. PMID: 41977236; PMCID: PMC13074000.
4. Cimini FA, Sentinelli F, Oldani A, Barchetta I, Cavallo MG. Adipose Tissue Dysfunction and Metabolic Diseases: The Role of Vitamin D/Vitamin D Receptor Axis. *Int J Mol Sci.* 2025 Oct 22;26(21):10256. doi: 10.3390/ijms262110256. PMID: 41226298; PMCID: PMC12610601.
5. Barchetta I, Filardi T, Dule S, Cimini FA, Sentinelli F, Romagnoli E, Passarella G, Bleve E, Oldani A, Venditti V, Anastasi E, Gandini O, Napoli N, Nicolucci A, Lenzi A, Baroni MG, Morano S, Cavallo MG; SlowDOWN Study Network. Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLOWDOWN (Sitagliptin in Diabetes for Osteoporosis in Women) randomized clinical trial. *BMC Med.* 2025 Oct 14;23(1):562. doi: 10.1186/s12916-025-04363-w. PMID: 41088165; PMCID: PMC12522551.
6. Barchetta I, Zampieri M, Cimini FA, Dule S, Sentinelli F, Passarella G, Oldani A, Karpach K, Bacalini MG, Baroni MG, Reale A, Cavallo MG. Association Between Active DNA Demethylation and Liver Fibrosis in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD). *Int J Mol Sci.* 2025 Jan 31;26(3):1271. doi: 10.3390/ijms26031271. PMID: 39941038; PMCID: PMC11818491.
7. Barchetta I, Dule S, Cimini FA, Sentinelli F, Oldani A, Passarella G, Filardi T, Venditti V, Bleve E, Romagnoli E, Morano S, Lenzi A, Melander O, Baroni MG, Cavallo MG. Circulating Proneurotensin Levels Predict Impaired Bone Mineralisation in Postmenopausal Women With Type 2 Diabetes Mellitus. *Diabetes Metab Res Rev.* 2025 Jan;41(1):e70018. doi: 10.1002/dmrr.70018. PMID: 39655684; PMCID: PMC11629440.
8. Totaro M, Barchetta I, Sentinelli F, Cimini FA, Palazzi S, D'Alessandro F, Spagnolo L, Dule S, Barbonetti A, Cavallo MG, Baroni MG. Waist circumference, among metabolic syndrome components, predicts degraded trabecular bone score: a retrospective study of a female population from the 2005-2008 NHANES cohorts. *Front Endocrinol (Lausanne).* 2024 Nov 21;15:1476751. doi: 10.3389/fendo.2024.1476751. PMID: 39640886; PMCID: PMC11617190.
9. Zampieri M, Karpach K, Salerno G, Raguzzini A, Barchetta I, Cimini FA, Dule S, De Matteis G, Zardo G, Borro M, Peluso I, Cavallo MG, Reale A. PAR level mediates the link between ROS and inflammatory response in patients with type 2 diabetes mellitus. *Redox Biol.* Sept 2024. <https://doi.org/10.1016/j.redox.2024.103243>
10. Lanzillotta C, Tramutola A, Lanzillotta S, Greco V, Pagnotta S, Sanchini C, Di Angelantonio S, Forte E, Rinaldo S, Paone A, Cutruzzola F, Cimini FA, Barchetta I, Cavallo MG, Urbani A, Butterfield DA, Di Domenico F, Paul BD, Perluigi M, Duarte JMN, Barone E. Biliverdin Reductase-A integrates insulin signaling with mitochondrial metabolism through phosphorylation of GSK3β. *Redox Biol.* 2024 Jul;73:103221. doi: 10.1016/j.redox.2024.103221. Epub 2024 Jun 1. PMID: 38843768.
11. Maddaloni E, Naciu AM, Mignogna C, Galiero R, Amendolara R, Fogolari M, Satta C, Serafini C, Angeletti S, Cavallo MG, Cossu E, Sasso FC, Buzzetti R, Pozzilli P; LADASAXADAPA study group. Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study. *Diabetes Obes Metab.* 2024 Jan 31. doi: 10.1111/dom.15469. Epub ahead of print. PMID: 38297915.
12. Barchetta I, Cimini FA, Sentinelli F, Chiappetta C, Di Cristofano C, Silecchia G, Leonetti F, Baroni MG,

Il presente *curriculum vitae*, è redatto ai fini della pubblicazione nella Sezione "Amministrazione trasparente" del sito web istituzionale dell'Ateneo al fine di garantire il rispetto della vigente normativa in materia di tutela dei dati. Il C.V. in versione integrale è conservato presso gli Uffici della Struttura che ha conferito l'incarico.

- Cavallo MG. Reduced Lipopolysaccharide-Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity. *Int J Mol Sci.* 2023 Dec 6;24(24):17174. doi: 10.3390/ijms242417174. PMID: 38139003; PMCID: PMC10742626.
13. Mantovani A, Morieri ML, Aldigeri R, Palmisano L, Masulli M, Bonomo K, Baroni MG, Cossu E, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Cas AD, de Kreutzenberg SV, Targher G. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. *Diabetes Metab.* 2023 Nov 20;50(1):101497. doi: 10.1016/j.diabet.2023.101497. Epub ahead of print. PMID: 37992857.
14. Csermely A, Mantovani A, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, Bonomo K, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Aldigeri R, Cas AD, de Kreutzenberg SV, Targher G. Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus. *Diabetes Metab.* 2023 Nov;49(6):101477. doi: 10.1016/j.diabet.2023.101477. Epub 2023 Sep 12. PMID: 37708990.
15. Mantovani A, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, Bonomo K, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Aldigeri R, Cas AD, de Kreutzenberg SV, Targher G. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus. *Cardiovasc Diabetol.* 2023 Aug 10;22(1):204. doi: 10.1186/s12933-023-01945-x. PMID: 37563618; PMCID: PMC10416459.
16. Cimini FA, Tramutola A, Barchetta I, Ceccarelli V, Gangitano E, Lanzillotta S, Lanzillotta C, Cavallo MG, Barone E. Dynamic Changes of BVRA Protein Levels Occur in Response to Insulin: A Pilot Study in Humans. *Int J Mol Sci.* 2023 Apr 14;24(8):7282. doi: 10.3390/ijms24087282. PMID: 37108445; PMCID: PMC10138944.
17. Dule S, Barchetta I, Cimini FA, Passarella G, Dellanno A, Filardi T, Venditti V, Blevé E, Bailetti D, Romagnoli E, Morano S, Baroni MG, Cavallo MG. Reduced High-Density Lipoprotein Cholesterol Is an Independent Determinant of Altered Bone Quality in Women with Type 2 Diabetes. *Int J Mol Sci.* 2023 Mar 30;24(7):6474. doi: 10.3390/ijms24076474. PMID: 37047445; PMCID: PMC10095189.
18. Sentinelli F, Barchetta I, Cimini FA, Dule S, Bailetti D, Cossu E, Barbonetti A, Totaro M, Melander O, Cavallo MG, Baroni MG. Neurotensin Gene rs2234762 C>G Variant Associates with Reduced Circulating Pro-NT Levels and Predicts Lower Insulin Resistance in Overweight/Obese Children. *Int J Mol Sci.* 2023 Mar 30;24(7):6460. doi: 10.3390/ijms24076460. PMID: 37047432; PMCID: PMC10095103.
19. Dei Cas A, Aldigeri R, Mantovani A, Masulli M, Palmisano L, Cavalot F, Bonomo K, Baroni MG, Cossu E, Cavallo G, Cimini FA, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Morieri ML, Pollis RM, Targher G, Vigili de Kreutzenberg S. Sex Differences in Cardiovascular Disease and Cardiovascular Risk Estimation in Patients With Type 1 Diabetes. *J Clin Endocrinol Metab.* 2023 Aug 18;108(9):e789-e798. doi: 10.1210/clinem/dgad127. PMID: 36881927.
20. Barchetta I, Lubrano C, Cimini FA, Dule S, Passarella G, Dellanno A, Di Biasio A, Leonetti F, Silecchia G, Lenzi A, Cavallo MG. Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease. *Hepatol Int.* 2023 Apr;17(2):357-366. doi: 10.1007/s12072-022-10461-1. Epub 2022 Dec 15. PMID: 36520377.
21. Barchetta I, Cimini FA, Dule S, Cavallo MG. Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis. *Biomedicines.* 2022 Sep 16;10(9):2306. doi: 10.3390/biomedicines10092306. PMID: 36140405; PMCID: PMC9496088.
22. Cimini FA, Perluigi M, Barchetta I, Cavallo MG, Barone E. Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. *Int J Mol Sci.* 2022 May 16;23(10):5574. doi: 10.3390/ijms23105574. PMID: 35628384; PMCID: PMC9141761.
23. Bailetti D, Sentinelli F, Prudente S, Cimini FA, Barchetta I, Totaro M, Di Costanzo A, Barbonetti A, Leonetti F, Cavallo MG, Baroni MG. Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans. *Int J Mol Sci.* 2022 Jan 22;23(3):1221. doi: 10.3390/ijms23031221. PMID: 35163144; PMCID: PMC8835579.
24. Cimini FA, Barchetta I, Bertocchini L, Ceccarelli V, Baroni MG, Melander O, Cavallo MG. High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up. *Acta Diabetol.* 2021 Aug 29. doi: 10.1007/s00592-021-01783-x.
25. Cimini FA, Barchetta I, Zuliani I, Pagnotta S, Bertocchini L, Dule S, Zampieri M, Reale A, Baroni MG, Cavallo MG, Barone E. Biliverdin reductase-A protein levels are reduced in type 2 diabetes and are associated with poor glycometabolic control. *Life Sci.* 2021 Aug 26;284:119913. doi: 10.1016/j.lfs.2021.119913.
26. Barchetta I, Dule S, Bertocchini L, Cimini FA, Sentinelli F, Bailetti D, Marini G, Barbonetti A, Loche S, Cossu E, Cavallo MG, Baroni MG. The single-point insulin sensitivity estimator (SPISE) index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study. *J Endocrinol Invest.* 2021 Jun 17. doi: 10.1007/s40618-021-01612-6.
27. Zampieri M, Bacalini MG, Barchetta I, Scalea S, Cimini FA, Bertocchini L, Tagliatesta S, De Matteis G, Zardo G, Cavallo MG, Reale A. Increased PARylation impacts the DNA methylation process in type 2 diabetes mellitus. *Clin Epigenetics.* 2021 May 17;13(1):114. doi: 10.1186/s13148-021-01099-1.
28. Barchetta I, Bertocchini L, Sentinelli F, Bailetti D, Marini G, Cimini FA, Ceccarelli V, Struck J, Schulte J, Loche S, Cossu E, Melander O, Cavallo MG, Baroni MG. Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children. *Nutr Metab Cardiovasc Dis.* 2021 Mar 10;31(3):902-910. doi: 10.1016/j.numecd.2020.11.025.
29. Cimini FA, Barchetta I, Ceccarelli V, Chiappetta C, Di Biasio A, Bertocchini L, Sentinelli F, Leonetti F,

- Silecchia G, Di Cristofano C, Baroni MG, Velotti F, Cavallo MG. Granzyme B Expression in Visceral Adipose Tissue Associates With Local Inflammation and Glyco-Metabolic Alterations in Obesity. *Front Immunol.* 2020 Nov 18;11:589188. doi: 10.3389/fimmu.2020.589188.
30. Velotti F, Barchetta I, Cimini FA, Cavallo MG. Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. *Front Immunol.* 2020 Nov 11;11:587581. doi: 10.3389/fimmu.2020.587581.
31. Ceccarelli V, Barchetta I, Cimini FA, Bertocchini L, Chiappetta C, Capoccia D, Carletti R, Di Cristofano C, Silecchia G, Fontana M, Leonetti F, Lenzi A, Baroni MG, Barone E, Cavallo MG. Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. *Int J Mol Sci.* 2020 Nov 29;21(23):9091. doi: 10.3390/ijms21239091.
32. Barchetta I, Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. *Nutrients.* 2020 Oct 28;12(11):E3302. doi: 10.3390/nu12113302.
33. Barchetta I, Cimini FA, Bertocchini L, Ceccarelli V, Spaccarotella M, Baroni MG, Cavallo MG. Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy. *Diabetes Res Clin Pract.* 2020 Oct 16;170:108513. doi: 10.1016/j.diabres.2020.108513.
34. Sentinelli F, Bertocchini L, Incani M, Barchetta I, Cimini FA, Mannino C, Lenzi A, Cavallo MG, Cossu E, Baroni MG. Association of Apelin Levels in Overweight-obese Children with Pubertal Development, but Not with Insulin Sensitivity: 6.5 Years Follow up Evaluation. *Endocr Res.* 2020 Aug 13:1-8. doi: 10.1080/07435800.2020.1804929
35. Barchetta I, Chiappetta C, Ceccarelli V, Cimini FA, Bertocchini L, Gaggini M, Cristofano CD, Silecchia G, Lenzi A, Leonetti F, Baroni MG, Gastaldelli A, Cavallo MG. Angiopietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. *Int J Mol Sci.* 2020 Sep 29;21(19):7197. doi: 10.3390/ijms21197197.
36. Barchetta I, Ceccarelli V, Cimini FA, Barone E, Sentinelli F, Coluzzi M, Chiappetta C, Bertocchini L, Tramutola A, Labbadia G, Di Cristofano C, Silecchia G, Leonetti F, Cavallo MG. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. *J Endocrinol Invest.* 2020 Aug 27.
37. Cimini FA, Barchetta I, Ciccarelli G, Leonetti F, Silecchia G, Chiappetta C, Di Cristofano C, Capoccia D, Bertocchini L, Ceccarelli V, Carletti R, Fraioli A, Baroni MG, Morini S, Cavallo MG. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. *Diabetes Metab Res Rev.* 2020 May 29:e3358.
38. Barchetta I, Cimini FA, Chiappetta C, Bertocchini L, Ceccarelli V, Capoccia D, Gaggini M, Di Cristofano C, Della Rocca C, Silecchia G, Leonetti F, Lenzi A, Gastaldelli A, Cavallo MG. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. *Liver Int.* 2020 Jun 8. doi: 10.1111/liv.14554.
39. Cimini FA, Barchetta I, Carotti S, Morini S, Cavallo MG. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. *World J Gastrointest Pathophysiol.* 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11.
40. Barchetta I, Ciccarelli G, Barone E, Cimini FA, Ceccarelli V, Bertocchini L, Sentinelli F, Tramutola A, Del Ben M, Angelico F, Baroni MG, Lenzi A, Cavallo MG. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis.* 2019 Oct;29(10):1087-1094.
41. Barchetta I, Cimini FA, Ciccarelli G, Baroni MG, Cavallo MG. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. *J Endocrinol Invest.* 2019 Nov;42(11):1257-1272.
42. Cimini FA, Arena A, Barchetta I, Tramutola A, Ceccarelli V, Lanzillotta C, Fontana M, Bertocchini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano C, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E. Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. *Biochim Biophys Acta Mol Basis Dis.* 2019 Jun 1;1865(6):1490-1501.
43. Bertocchini L, Sentinelli F, Incani M, Bailetti D, Cimini FA, Barchetta I, Lenzi A, Cavallo MG, Cossu E, Baroni MG. Circulating miRNA-375 levels are increased in autoantibodies-positive first-degree relatives of type 1 diabetes patients. *Acta Diabetol.* 2019 Jun;56(6):707-710. doi: 10.1007/s00592-019-01297-7.
44. Cimini FA, D'Eliseo D, Barchetta I, Bertocchini L, Velotti F, Cavallo MG. Increased circulating granzyme B in type 2 diabetes patients with low-grade systemic inflammation. *Cytokine.* 2019 Mar;115:104-108.
45. Barchetta I, Ceccarelli V, Cimini FA, Bertocchini L, Fraioli A, Alessandri C, Lenzi A, Baroni MG, Cavallo MG. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. *J Endocrinol Invest.* 2019 May;42(5):513-520.
46. Barchetta I, Cimini FA, Capoccia D, Bertocchini L, Ceccarelli V, Chiappetta C, Leonetti F, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo MG. Neurotensin Is a Lipid- Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. *Nutrients.* 2018 Apr 23;10(4). pii: E526.
47. Barchetta I, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo MG. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. *J Clin Endocrinol Metab.* 2018 Jun 1;103(6):2253- 2260.
48. Barchetta I, Cimini FA, De Gioannis R, Ciccarelli G, Bertocchini L, Lenzi A, Baroni MG, Cavallo MG. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. *Diabetes Metab Res Rev.* 2018 Jul;34(5):e2998.
49. Barchetta I, Ciccarelli G, Cimini FA, Ceccarelli V, Orho-Melander M, Melander O, Cavallo MG. Association between systemic leptin and neurotensin concentration in adult individuals with and without type 2 diabetes mellitus. *J Endocrinol Invest.* 2018 Oct;41(10):1159-1163.
50. Cossu E, Incani M, Pani MG, Gattu G, Serafini C, Strazzera A, Bertocchini L, Cimini FA, Barchetta I, Cavallo MG, Baroni MG. Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up. *J Endocrinol Invest.* 2018

Sep;41(9):1061-1068.

51. Barchetta I, Cimini FA, Capoccia D, De Gioannis R, Porzia A, Mainiero F, Di Martino M, Bertocchini L, De Bernardinis M, Leonetti F, Baroni MG, Lenzi A, Cavallo MG. WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes. J Endocr Soc. 2017 Apr 18;1(6):660-670.

52. Bertocchini L, Sentinelli F, Incani M, Bailetti D, Cimini FA, Barchetta I, Cavallo MG, Cossu E, Lenzi A, Loche S, Baroni MG. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V. Lipids Health Dis. 2017 Sep 19;16(1):179.

53. Barchetta I, Cimini FA, Cavallo MG. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. Nutrients. 2017 Sep 14;9(9). pii: E1015.

54. Cimini FA, Barchetta I, Porzia A, Mainiero F, Costantino C, Bertocchini L, Ceccarelli V, Morini S, Baroni MG, Lenzi A, Cavallo MG. Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetol. 2017 Oct;54(10):961-967.

55. Cimini FA, Barchetta I, Carotti S, Bertocchini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2017 May 21;23(19):3407-3417.

56. Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertocchini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. Comment on Elangovan H et al. vitamin D in liver disease: Current evidence and potential directions. Biochim Biophys Acta 2017;1863(4):907-916. Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2388.

57. Barchetta I, Enhörning S, Cimini FA, Capoccia D, Chiappetta C, Di Cristofano C, Silecchia G, Leonetti F, Melander O, Cavallo MG. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. BMC Med. 2019 Apr 30;17(1):85.

58. Bertocchini L, Sentinelli F, Leonetti F, Bailetti D, Capoccia D, Cimini FA, Barchetta I, Incani M, Lenzi A, Cossu E, Cavallo MG, Baroni MG. The vitamin D receptor functional variant rs2228570 (C>T) does not associate with type 2 diabetes mellitus. Endocr Res. 2017 Nov;42(4):331-335.

59. Barchetta I, Angelico F, Del Ben M, Di Martino M, Cimini FA, Bertocchini L, Polimeni L, Catalano C, Fraioli A, Del Vesco R, Morini S, Baroni MG, Cavallo MG. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. Clin Sci (Lond). 2016 Oct 1;130(19):1753-62.

60. Barchetta I, Cimini FA, Bloise D, Cavallo MG. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link? Acta Diabetol. 2016 Oct;53(5):839-44.

61. Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertocchini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016 Jun 29;14:92.

62. Barchetta I, Alessandri C, Bertocchini L, Cimini FA, Tavemiti L, Di Franco M, Fraioli A, Baroni MG, Cavallo MG. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur J Endocrinol. 2016 Feb; 174(2):187-92.

Dati personali Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

La sottoscritta dichiara di essere consapevole che il presente *curriculum vitae* sarà pubblicato sul sito istituzionale dell'Ateneo, nella Sezione "Amministrazione trasparente", nelle modalità e per la durata prevista dal d.lgs. n. 33/2013, art. 15.

9/06/2026

f.to Flavia Agata Cimini

Il presente *curriculum vitae*, è redatto ai fini della pubblicazione nella Sezione "Amministrazione trasparente" del sito web istituzionale dell'Ateneo al fine di garantire il rispetto della vigente normativa in materia di tutela dei dati. Il C.V. in versione integrale è conservato presso gli Uffici della Struttura che ha conferito l'incarico.